Drug voyager: a computational platform for exploring unintended drug action

Abstract

BackgroundThe dominant paradigm in understanding drug action focuses on the intended therapeutic effects and frequent adverse reactions. However, this approach may limit opportunities to grasp unintended drug actions, which can open up channels to repurpose existing drugs and identify rare adverse drug reactions. Advances in systems biology can be exploited to comprehensively understand pharmacodynamic actions, although proper frameworks to represent drug actions are still lacking.ResultsWe suggest a novel platform to construct a drug-specific pathway in which a molecular-level mechanism of action is formulated based on pharmacologic, pharmacogenomic, transcriptomic, and phenotypic data related to drug response (http://databio.gachon.ac.kr/tools/). In this platform, an adoption of three conceptual levels imitating drug perturbation allows these pathways to be realistically rendered in comparison to those of other models. Furthermore, we propose a new method that exploits functional features of the drug-specific pathways to predict new indications as well as adverse reactions. For therapeutic uses, our predictions significantly overlapped with clinical trials and an up-to-date drug-disease association database. Also, our method outperforms existing methods with regard to classification of active compounds for cancers. For adverse reactions, our predictions were significantly enriched in an independent database derived from the Food and Drug Administration (FDA) Adverse Event Reporting System and meaningfully cover an Adverse Reaction Database provided by Health Canada. Lastly, we discuss several predictions for both therapeutic indications and side-effects through the published literature.ConclusionsOur study addresses how we can computationally represent drug-signaling pathways to understand unintended drug actions and to facilitate drug discovery and screening.Electronic supplementary materialThe online version of this article (doi:10.1186/s12859-017-1558-3) contains supplementary material, which is available to authorized users.

Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs

“…Several biological and chemical databases for therapeutic and experimental drugs have been constructed. In particular, databases such as the National Institute of Mental Health Psychoactive Drug Screening Programme 9 , Receptoromics 10 , Drug Voyager 11 , PubChem 12 , Ligand Expo 13 , ZINC 14 , STITCH 15 and KEGG DRUG 16 have been developed that integrate diverse information such as compound structures, drug targets, and molecular pathways modulated in a biological system. While these databases provide useful information for drug discovery and repurposing processes, they focus on the chemical and molecular level (i.e.…”

Drug repositioning using drug-disease vectors based on an integrated network

“…Several studies tried to establish mechanisms of drugs for diseases using pathways between the drugs and diseases [ 21 – 23 ]. We showed that our candidate drugs were more functionally similar to known drugs for diseases than non-candidate drugs, using functional modules obtained from pathways between drugs and diseases.…”

Computational chemical biology and drug design: Facilitating protein structure, function, and modulation studies

“…In particular, genome‐wide expression data can be used to profile the effect of drug activity and discover candidates for drug repurposing . Oh et al have devised a new platform, Drug Voyager, to construct a drug‐ signaling pathways. In this platform, three conceptual levels, “initiation,” “perturbation,” and “destination,” represent the molecular‐level action of a drug.…”